The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults and children aged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback